Our client needed to establish the minimum budget impact that could legitimately be claimed for the introduction of a new technology that involved changes in pathways of care.
Translucency conducted a 360o assessment of the potential impact of the new technology using SIM®, its proprietary approach for comprehensive integral analysis of changing existing Chemins cliniques/stratégies thérapeutiques. Using its experience of management of health services, Translucency generated real-world costs and savings. Assumptions and estimates were tested on focus groups of key decision makers. Budget impact was calculated for a number of scenarios involving different target groups of patients.
A briefing paper was prepared for the client setting out the estimated budget impact of a range of choices as to product positioning. An interactive model was prepared for use with our client’s customers.
Our client used the briefing paper to clarify the positioning of choice. The model was used to support a client’s successful submission to both NICE and the Scottish Medicines Consortium, and has subsequently used locally to encourage the inclusion of our client’s product into formularies.